'Milestone' Discussions With US FDA On OTC Monograph Proposals Limited To One Meeting
With Monograph Order Request Meetings, Agency Will Serve Unpaid User Fee Notices
Executive Summary
Recent draft guidance on scheduling and conducting meetings with FDA supported by OTC monograph user fees largely tracks with agency’s guidance for meetings supported by other user fee programs, such as PDUFA.
You may also be interested in...
Timers Start Ticking At US FDA In A Month For An Even Dozen OTC Monograph Meeting Requests
CDER Office of Nonprescription Drugs already accepts requests but won’t start responding until FY2023 begins on 1 October, also the start of FDA’s first year meeting with firms developing monograph changes and evaluating submitted proposals under deadlines included in program overhaul Congress authorized in 2020.
Strides Pharma Reaches 9 US OTCs With Naproxen
Recent approval of Indian firm’s ANDA for 220-mg naproxen capsules comes as NDA process for launching OTCs in US soon could take a back seat to overhauled monograph program the pharma industry prepares to start using on 1 October.
OTC Monograph Stakeholders Seek Confidentiality Assurances Ahead Of OMOR Meetings With FDA
Judging by January draft guidance from the US FDA, the agency may feel compelled to make public any information a party submits in the context of a meeting to discuss data needs for an OTC monograph change. And special sunscreen considerations included in the CARES Act, which overhauled the FDA's OTC drug review program, aren't mentioned in the guidance, trade groups say.